ReviewInternational journal of molecular sciences2022
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The psychedelic-peptide paradox: a hormetic hypothesis.Comprehensive psychoneuroendocrinology · 2025Review
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
- Biological Susceptibility of Patients with Schizophrenia to Metabolic Syndrome: A Review.Alpha psychiatry · 2025Review
- Neuropeptidergic systems in psychiatric disorders.Frontiers in endocrinology · 2025Review
- Clostridium butyricum CGMCC 0313.1 improves clinical outcomes of metabolic syndrome in schizophrenic patients.American journal of translational research · 2025Article
- Knowledge, Attitude, and Practice of Medical Staff Towards Metabolic Syndrome in Schizophrenia in Chinese Hospitals: A Cross-Sectional Study.Journal of multidisciplinary healthcare · 2025Article
- A clinical prediction model for schizophrenia based on machine learning algorithms.Frontiers in medicine · 2025Article
- Serum Uric Acid and Iron Status: Exploring a Complex Interaction in Metabolic Syndrome Patients of Eastern India.Cureus · 2024Article
- Sex differences in the association between metabolic disorder and inflammatory cytokines in Han Chinese patients with chronic schizophrenia.Frontiers in psychiatry · 2024Article
- Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.Frontiers in psychiatry · 2024Review
- A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia.Frontiers in psychiatry · 2024Review
- Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review.Experimental and therapeutic medicine · 2023Article
- The Role of Oxytocin in Early-Life-Stress-Related Neuropsychiatric Disorders.International journal of molecular sciences · 2023Review
- Molecular Research on Mental Disorders.International journal of molecular sciences · 2023Article
- Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review).Experimental and therapeutic medicine · 2023Review
- Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis.Neuropsychiatric disease and treatment · 2023Article
- Schizophrenia and cardiometabolic abnormalities: A Mendelian randomization study.Frontiers in genetics · 2023Article
- Association between Insertion-Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Treatment Response to Antipsychotic Medications: A Study of Antipsychotic-Naïve First-Episode Psychosis Patients and Nonadherent Chronic Psychosis Patients.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The high prevalence of metabolic syndrome in persons with schizophrenia has spurred investigational efforts to study the mechanism beneath its pathophysiology. Early psychosis dysfunction is present across multiple organ systems. On this account, schizophrenia may be a multisystem disorder in which one organ system is predominantly affected and where other organ systems are also concurrently involved. Growing evidence of the overlapping neurobiological profiles of metabolic risk factors and psychiatric symptoms, such as an association with cognitive dysfunction, altered autonomic nervous system regulation, desynchrony in the resting-state default mode network, and shared genetic liability, suggest that metabolic syndrome and schizophrenia are connected via common pathways that are central to schizophrenia pathogenesis, which may be underpinned by oxytocin system dysfunction. Oxytocin, a hormone that involves in the mechanisms of food intake and metabolic homeostasis, may partly explain this piece of the puzzle in the mechanism underlying this association. Given its prosocial and anorexigenic properties, oxytocin has been administered intranasally to investigate its therapeutic potential in schizophrenia and obesity. Although the pathophysiology and mechanisms of oxytocinergic dysfunction in metabolic syndrome and schizophrenia are both complex and it is still too early to draw a conclusion upon, oxytocinergic dysfunction may yield a new mechanistic insight into schizophrenia pathogenesis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.